These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11420466)

  • 1. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis.
    Southey MC; Young MA; Whitty J; Mifsud S; Keilar M; Mead L; Trute L; Aittomäki K; McLachlan SA; Debinski H; Venter DJ; Armes JE
    Am J Surg Pathol; 2001 Jul; 25(7):936-41. PubMed ID: 11420466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
    Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
    Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
    Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
    Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
    Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
    J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
    Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
    Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
    Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
    J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
    Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
    Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Muir-Torre syndrome and Turcot syndrome].
    Velter C; Caussade P; Fricker JP; Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene?
    Kruse R; Lamberti C; Wang Y; Ruelfs C; Bruns A; Esche C; Lehmann P; Ruzicka T; Rütten A; Friedl W; Propping P
    Hum Genet; 1996 Dec; 98(6):747-50. PubMed ID: 8931714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
    Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
    J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
    Vernez M; Hutter P; Monnerat C; Halkic N; Gugerli O; Bouzourene H
    Fam Cancer; 2007; 6(1):141-5. PubMed ID: 17051350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mutation in the MSH2 gene in Muir-Torre syndrome].
    Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
    Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
    Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
    Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Muir-Torre syndrome].
    Körber J; Djawari D
    Hautarzt; 2001 Dec; 52(12):1107-10. PubMed ID: 11910863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome.
    Peris K; Onorati MT; Keller G; Magrini F; Donati P; Muscardin L; Höfler H; Chimenti S
    Br J Dermatol; 1997 Sep; 137(3):356-60. PubMed ID: 9349329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
    Chhibber V; Dresser K; Mahalingam M
    Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Muir-Torre syndrome].
    Jonas J; Kruse R; Bähr R
    Chirurg; 2002 Apr; 73(4):366-9. PubMed ID: 12063922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.